Celcuity

• Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)

  Phase 3, Recruiting, 1,180 people, 3 Jan 2025

• NCT05501886

  Phase 3, Active, not recruiting, 701 people, 16 Aug 2022

• NCT04901299

  Collaborator, Phase 2, Withdrawn, 0 people, 25 May 2021

• NCT03675893

  Collaborator, Phase 2, Recruiting, 110 people, 18 Sept 2018

• NCT03412643

  Collaborator, Phase 2, Status unknown, 64 people, 26 Jan 2018

• NCT02684032

  Phase 1, Completed, 141 people, 17 Feb 2016

Sources: clinicaltrials.gov